Literature DB >> 10090132

Analysis of splice variants of the fibronectin gene in thyroid carcinomas by reverse transcription-polymerase chain reaction: increased expression of oncofetal fibronectin mRNA in papillary carcinomas is not caused by the alternation in splicing.

T Takano1, F Matsuzuka, G Liu, A Miyauchi, T Yokozawa, K Kuma, N Amino.   

Abstract

The expression levels of each splice variant of the fibronectin gene in the normal thyroid and in thyroid tumors were examined by reverse transcription-polymerase chain reaction (RT-PCR). In thyroid papillary carcinomas, insertion of a variant exon in the ED-A and ED-B domains, and three of five types of splice variants in the IIICS domain were observed. In spite of the marked increase in the expression of oncofetal fibronectin mRNA with the IIICS sequence in papillary and anaplastic carcinomas in the previous reports, the relative expression levels of each splice variant with or without the IIICS sequence showed no difference among all the tumor types. Therefore, the much increased expression of oncofetal fibronectin mRNA in these carcinomas is not caused by the alternation in splicing, but may be caused by an increase in promoter activity or stability of mRNA of the fibronectin gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090132     DOI: 10.1007/BF03345473

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy.

Authors:  T Yokozawa; A Miyauchi; K Kuma; M Sugawara
Journal:  Thyroid       Date:  1995-04       Impact factor: 6.568

2.  Three different fibronectin mRNAs arise by alternative splicing within the coding region.

Authors:  J E Schwarzbauer; J W Tamkun; I R Lemischka; R O Hynes
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

3.  Detection of CD44 variants in fine needle aspiration biopsies of thyroid tumor by RT-PCR.

Authors:  T Takano; H Sumizaki; N Amino
Journal:  J Exp Clin Cancer Res       Date:  1997-09

4.  Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma.

Authors:  T Takano; F Matsuzuka; H Sumizaki; K Kuma; N Amino
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

5.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

6.  Human cellular fibronectin: comparison of the carboxyl-terminal portion with rat identifies primary structural domains separated by hypervariable regions.

Authors:  M P Bernard; M Kolbe; D Weil; M L Chu
Journal:  Biochemistry       Date:  1985-05-21       Impact factor: 3.162

7.  Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein.

Authors:  V Iotsova; D Stehelin
Journal:  Cell Growth Differ       Date:  1996-05

8.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

9.  Multiple sites of alternative splicing of the rat fibronectin gene transcript.

Authors:  J E Schwarzbauer; R S Patel; D Fonda; R O Hynes
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Increased expression of CD44 variants in differentiated thyroid cancers.

Authors:  T Takano; H Sumizaki; K Nakano; F Matsuzuka; K Kuma; N Amino
Journal:  Jpn J Cancer Res       Date:  1996-12
View more
  1 in total

1.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.